<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">MarketBeat</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketbeat.com/stock-ideas/giants-costco-sanofi-and-sap-raise-dividends-by-over-10/?utm_source=snapi">Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%</a>
    </div>

      <div class="me-0 me-md-5">
        Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing performance, continue to make good on their commitments to return more capital to shareholders.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/investing/2026/04/25/3-healthcare-stocks-that-pay-you-a-dividend-while/">3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery</a>
    </div>

      <div class="me-0 me-md-5">
        Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/24/3281028/0/en/Press-Release-Sanofi-successfully-prices-2-3-billion-of-bond-issue.html">Press Release: Sanofi successfully prices 2.3 billion of bond issue</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi successfully prices 2.3 billion of bond issue   Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches:  €1,000 million fixed-rate notes, due May 2029, bearing interest at an annual rate of 3.000%  €650 million fixed-rate notes, due May 2033, bearing interest at an annual rate of 3.375%  €650 million fixed-rate not...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/24/3280641/0/en/Press-Release-Sanofi-s-Cenrifki-tolebrutinib-recommended-for-EU-approval-by-the-CHMP-to-treat-secondary-progressive-multiple-sclerosis-without-relapses.html">Press Release: Sanofi&#39;s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi&#39;s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/business/earnings/sanofi-posts-higher-sales-amid-leadership-transition-7a7e2f3f">Sanofi Posts Higher Sales Amid Leadership Transition</a>
    </div>

      <div class="me-0 me-md-5">
        Sales rose 14% to €10.51 billion at constant currency, boosted by new launches and recent acquisitions.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/sanofis-first-quarter-earnings-edges-past-estimates-ahead-ceo-change-2026-04-23/">Sanofi&#39;s first quarter earnings edges past estimates ahead of CEO change</a>
    </div>

      <div class="me-0 me-md-5">
        French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted ​by resilient demand for its blockbuster asthma and ‌eczema drug Dupixent.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/22/3279472/0/en/Press-Release-Sanofi-and-Regeneron-s-Dupixent-approved-in-the-US-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria.html">Press Release: Sanofi and Regeneron&#39;s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi and Regeneron&#39;s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Sanofi-Sponsored-ADR-US80105N1054">Sanofi Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/04/22/3278650/0/en/Press-Release-Sanofi-s-Tzield-approved-in-the-US-to-delay-the-onset-of-stage-3-type-1-diabetes-in-young-children.html">Press Release: Sanofi&#39;s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children</a>
    </div>

      <div class="me-0 me-md-5">
        Sanofi&#39;s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of stage 3 Tzield is the first disease-modifying therapy for children aged one year and above diagnosed with stage 2 T1D Paris, April 22, 2026. The US Food and Drug Administration (FDA) has approved the...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Sanofi-Sponsored-ADR-US80105N1054/load_more?page=7">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>